Incyte Corporation INCY SPX

Q: What is the current share price of Incyte Corporation (INCY)?

As of 2026-07-14 21:23 PDT, Incyte Corporation (INCY) trades at $114.88 on NasdaqGS. Its 52-week range is $67.38 to $118.52.

Q: What is the market capitalisation of INCY?

Incyte Corporation (INCY) has a market capitalisation of $22.95B on NasdaqGS.

Q: What is the P/E ratio of INCY?

INCY trades at a trailing price-to-earnings (P/E) ratio of 16.23. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.86.

Q: What is the return on equity (ROE) of INCY?

INCY has a return on equity (ROE) of 30.82%. Its return on capital employed (ROCE) is 27.83%.

Q: Is INCY a good stock to buy?

This page provides a data-driven analysis of Incyte Corporation (INCY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.incyte.com

Company Profile ↓

$114.88

+64.16% 1Y

Mkt Cap$22.95B

P/E16.23

P/B3.86

52W High$118.52

52W Low$67.38

Book Value$28.12

EPS (TTM)$7.08

Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 30.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 27.8%.

Steady Revenue Expansion

Revenue has grown at a 48.4% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 16.2, below the sector median of 25.4.

Healthy Margins

Maintains a net profit margin of 26.7%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $5.14B (+21.2% YoY); net profit $1.29B.
Trailing 12 Months Year-on-year growth — revenue +20.9%, earnings +83.8%.
5-Year Trend Long-term compounding — revenue CAGR 48.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	48.43%
1 Year:	20.90%

Compounded Profit Growth

5 Years:	-
1 Year:	83.80%

Stock Price Performance

1 Year:	+64.16%
6 Months:	+7.50%
3 Months:	+20.23%
1 Month:	+6.54%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 93% of range

$67.38 $118.52

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)60.19 · Neutral

Price Performance

1M+6.54%

3M+20.23%

6M+7.50%

1Y+64.16%

Valuation vs Sector

P/E of 16.23 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 30.8%.
Healthy ROCE of 27.8%.
Excellent profit margin of 26.7%.
Compounding revenue at 48.4% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

16.23

Industry PE

25.41

Forward P/E

12.54

PEG Ratio

0.36

Book Value

$28.12

Price to Book

3.86

P/S

4.04

EV/EBITDA

11.43

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

48.43%

Profit 5Y

Revenue (YoY)

20.90%

Earnings (YoY)

83.80%

Profitability & Returns

ROCE

27.83%

ROE

30.82%

ROA

13.89%

Profit Margin

26.71%

Op Margin

25.55%

Gross Margin

52.77%

EPS (Latest Qtr)

$1.47

EPS (TTM)

$7.08

Balance Sheet & Liquidity

Debt/Equity

0.70

Quick Ratio

3.40

Current Ratio

3.68

Debt

$39.43M

Total Assets

$7.34B

Current Assets

Working Capital

Ownership

Promoter Holding

1.88%

Chg in Prom Hold

FII / Inst Holding

106.57%

Chg in FII Hold

-0.05%

Financial Snapshot

Enterprise Value

$22.95B

Total Revenue (TTM)

$5.36B

EBITDA

$1.55B

Free Cash Flow

$558.87M

Operating Cash Flow

$1.52B

Shares Outstanding

199.78M

Gross Margin

52.77%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	INCY Incyte Corporation SPX	114.88	16.23	$22.95B	0.00%	27.83%	30.82%	48.43%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	384.08M	326.44M	381.53M	444.16M	382.28M	521.52M	449.68M	528.40M	497.86M	529.93M	551.58M	579.39M	568.51M	688.04M	620.64M	789.51M	604.72M	705.71M	812.99M	733.24M	911.40M	823.30M	808.67M	954.61M	919.02M	880.89M	1.04B	1.14B	1.05B	1.22B	1.37B	1.27B
Operating Income	-6.93M	-7.39M	-101.00K	-	36.04M	44.59M	22.29M	-	-133.25M	7.26M	15.02M	-	-67.11M	83.24M	31.12M	-	74.07M	98.61M	134.32M	-	-664.00M	230.77M	5.33M	-	98.80M	140.84M	235.41M	116.54M	254.43M	138.38M	24.77M	193.78M	214.71M	91.90M	-478.13M	146.09M	205.17M	530.31M	443.52M	301.12M
Net Income	-	-	-	-	-	-	-	-	-187.08M	-12.48M	36.05M	-149.63M	-41.14M	52.39M	29.18M	69.06M	102.31M	105.32M	128.27M	111.00M	-720.64M	290.30M	-15.20M	149.85M	53.53M	149.46M	181.74M	37.99M	161.43M	112.78M	21.70M	203.55M	171.27M	169.55M	-444.60M	106.46M	158.20M	405.00M	424.17M	303.33M
Diluted EPS	-0.11	0.05	-0.22	0.29	0.12	0.18	0.19	0.05	-0.96	-0.06	0.17	-0.71	-0.19	0.24	0.14	0.32	0.47	0.48	0.59	0.51	-3.33	1.32	-0.07	0.68	0.24	0.67	0.82	0.17	0.72	0.50	0.10	0.90	0.76	0.75	-2.04	0.54	0.80	2.04	2.11	1.47
R&D Expense	118.36M	112.44M	132.07M	-	156.82M	120.27M	143.18M	-	407.92M	201.79M	269.56M	-	303.10M	298.09M	292.53M	-	270.55M	289.36M	281.34M	-	1.09B	286.60M	438.11M	-	306.90M	343.51M	334.94M	353.37M	347.20M	384.01M	406.64M	400.75M	375.71M	429.26M	1.14B	573.17M	437.28M	494.92M	506.58M	515.90M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	9.27M	169.88M	94.45M	297.06M	354.95M	511.50M	753.75M	1.11B	1.54B	1.88B	2.16B	2.67B	2.99B	3.39B	3.70B	4.24B	5.14B
Operating Income	-139.77M	14.05M	-143.18M	1.15M	-16.10M	-4.80M	50.65M	145.00M	-243.39M	129.22M	402.01M	-263.68M	585.78M	579.44M	620.52M	61.37M	1.51B
Net Income	-211.87M	-31.85M	-186.54M	-44.32M	-83.15M	-48.48M	6.53M	104.22M	-313.14M	109.49M	446.91M	-295.70M	948.58M	340.66M	597.60M	32.62M	1.29B
Diluted EPS	-	-	-	-	-0.56	-0.29	0.03	0.54	-1.53	0.51	2.05	-1.36	4.27	1.52	2.65	0.15	6.41
R&D Expense	119.44M	123.88M	178.71M	210.39M	260.44M	347.52M	479.51M	581.86M	1.33B	1.20B	1.15B	2.22B	1.46B	1.59B	1.63B	2.61B	2.05B

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	489.58M	328.96M	330.42M	629.57M	796.48M	1.01B	1.64B	2.30B	2.65B	3.43B	3.56B	4.93B	5.84B	6.78B	5.44B	6.96B
Total Equity	-220.75M	-102.38M	-88.64M	-227.08M	-174.96M	-193.11M	-81.63M	171.16M	419.47M	1.63B	1.93B	2.60B	2.61B	3.77B	4.37B	5.19B	3.45B	5.17B
Cash & Equivalents	178.77M	449.82M	417.91M	273.16M	224.06M	471.43M	452.30M	521.44M	652.34M	899.51M	1.16B	1.83B	1.51B	2.06B	2.95B	3.21B	1.69B	3.10B
Long Term Debt	-	-	293.43M	316.15M	410.00M	846.60M	840.90M	749.80M	749.80M	26.80M	19.09B	-	-	-	-	-	-	-
Total Liabilities	-	-	578.23M	556.04M	505.38M	822.68M	878.11M	836.28M	1.22B	671.95M	719.79M	828.34M	949.65M	1.16B	1.47B	1.59B	2.00B	1.79B
Current Liabilities	-	-	113.57M	135.61M	136.07M	108.04M	221.06M	168.01M	273.50M	375.40M	425.28M	513.34M	631.20M	854.31M	1.16B	1.24B	1.64B	1.52B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	89.41M	304.76M	-92.99M	336.23M	710.66M	-124.60M	749.49M	969.94M	496.49M	335.34M	1.41B
Investing Cash Flow	-105.01M	-232.49M	-349.98M	-86.42M	-87.45M	-269.00M	-207.70M	-78.54M	-207.68M	157.52M	-102.61M
Financing Cash Flow	84.74M	44.62M	690.21M	14.66M	45.71M	71.71M	6.18M	-794.00K	-20.03M	-2.02B	101.04M
Share Buybacks	-	-	-	-	-	-	-	0	0	2.00B	0

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-1,508.6%	8.3%	-151.6%	0.4%	-4.5%	-0.9%	6.7%	13.1%	-15.8%	6.9%	18.6%	-9.9%	19.6%	17.1%	16.8%	1.4%	29.5%
Net Margin %	-2,286.8%	-18.7%	-197.5%	-14.9%	-23.4%	-9.5%	0.9%	9.4%	-20.4%	5.8%	20.7%	-11.1%	31.8%	10.0%	16.2%	0.8%	25.0%
ROE %	206.9%	35.9%	82.1%	25.3%	43.1%	59.4%	3.8%	24.8%	-19.2%	5.7%	17.2%	-11.3%	25.2%	7.8%	11.5%	0.9%	24.9%
ROCE %	-	3.7%	-74.1%	0.6%	-3.1%	-0.8%	6.0%	10.6%	-12.6%	5.8%	13.8%	-9.0%	14.4%	12.4%	11.2%	1.6%	27.8%

Shareholding Pattern

Insiders

1.88%

Institutions

106.57%

Public Float

108.61%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Baker Bros. Advisors, LP	15.39%	30.74M	$3.56B
2	Blackrock Inc.	9.50%	18.98M	$2.20B
3	Dodge & Cox Inc.	6.13%	12.25M	$1.42B
4	Vanguard Capital Management LLC	5.47%	10.93M	$1.27B
5	State Street Corporation	4.83%	9.64M	$1.12B
6	Vanguard Portfolio Management LLC	3.88%	7.76M	$898.90M
7	AQR Capital Management, LLC	2.91%	5.81M	$672.85M
8	Geode Capital Management, LLC	2.35%	4.70M	$544.86M
9	LSV Asset Management	1.96%	3.92M	$454.14M
10	Invesco Ltd.	1.94%	3.87M	$448.43M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INCY

Google News ue, 14 Jul 2026

INCY Maintains Overweight Rating -- Price Target Raised to $134 - GuruFocus

<a href="https://news.google.com/rss/articles/CBMiwgJBVV95cUxNelFzUFZRVUlZdXU5emZ3WmppY01PNmxLRXFOcXMzRzhYSjkwS28xOG52cV92VHpXSHMzamtfMk5mV2YtaUZ4dmRyNW5XbnZkYVVOd3d6dU1LNV9ONEtPMW5ZRlBmbmlVVVk2c3FPVnRERWc4Y2dMNEZaSFM4bFVXc1Z5MXVrSzR1NmNOQl…

Google News Mon, 13 Jul 2026

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcn…

Google News Wed, 01 Jul 2026

Incyte (INCY) Stock May Be 33% Overvalued After Opzelura EU Win - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNNndzaS1JdTM4OW1WNFI5V3ZwSVpHZWpjTjlXdEt0eUlsR01jUDJRcHk3VVRZS3VsN3JSV2daSnI1b3RpeUhFNXZhRUF3XzQ1cVhyc3hTUE5OT3N2ZHBRNjBBYjA4bVFoLW1JenhoR2VBcUpIVW9kMWdTRHNPazdtdktOcGpDT0tlTmRoYj…

Google News Mon, 26 Jan 2026

INCY Stock Price and Chart — NASDAQ:INCY - TradingView

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE52MEF3WHRDbDVpZHhrc3B4ejdpZWFNQXR0MElhRVFBdHNsRzZnVHB1WEtzaTdnbUp0S3N2UC1DZlRMRHZubHh5dUhVcFdwUm0zUFRNN1JNOTMzdy1L?oc=5" target="_blank">INCY Stock Price and Chart — NASDAQ:INCY</a…

Google News Mon, 29 Jun 2026

Incyte: New Catalysts Support Another Leg Higher - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNNVZfS21Ealp0QnpHZ2JmYS1LYXJucnZNcFZBaFlpZ3o2VFJJU1lOdUlYR09oZjZsb2JwZGtEM2pHQXhtam10OGdfek4wV0JMeUZhSV9MdXU0LUVkMnhleDB6bFZXakY5dXgtOVJvZVJXSGh4QVluMVIzN2RhNGdRWmRVelpHX1FqM191LW…

Google News Wed, 03 Jun 2026

Incyte shares rise 6.2% amid renewed optimism around late-stage pipeline and recent partnership update - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOenVCZlpfeW9CNXJCUmhoeUM1YWRHaHlZdnNadUhBTUpNTl9ZUmlXdHo5VHhEWWhpeHdPTFV2UTl5TmJfalp6b1dvdGMzV3hNQXI5Wm1zQmlaWVNvdkJZY2ZUMmlUTXdjZWJtRkJCTjBtQTBkejA0U1ZBN2FEZElDWlVqcjNwYmh2UXloUj…

INCY — Frequently Asked Questions

What is the current share price of Incyte Corporation (INCY)?

As of 2026-07-14 21:23 PDT, Incyte Corporation (INCY) trades at $114.88 on NasdaqGS. Its 52-week range is $67.38 to $118.52.

What is the market capitalisation of INCY?

Incyte Corporation (INCY) has a market capitalisation of $22.95B on NasdaqGS.

What is the P/E ratio of INCY?

INCY trades at a trailing price-to-earnings (P/E) ratio of 16.23. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.86.

What is the return on equity (ROE) of INCY?

INCY has a return on equity (ROE) of 30.82%. Its return on capital employed (ROCE) is 27.83%.

Is INCY a good stock to buy?

This page provides a data-driven analysis of Incyte Corporation (INCY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Incyte Corporation INCY SPX

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

INCY Maintains Overweight Rating -- Price Target Raised to $134 - GuruFocus

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks - Yahoo Finance

Incyte (INCY) Stock May Be 33% Overvalued After Opzelura EU Win - simplywall.st

INCY Stock Price and Chart — NASDAQ:INCY - TradingView

Incyte: New Catalysts Support Another Leg Higher - Seeking Alpha

Incyte shares rise 6.2% amid renewed optimism around late-stage pipeline and recent partnership update - Quiver Quantitative

INCY — Frequently Asked Questions

What is the current share price of Incyte Corporation (INCY)?

What is the market capitalisation of INCY?

What is the P/E ratio of INCY?

What is the return on equity (ROE) of INCY?

Is INCY a good stock to buy?

Explore More